Dublin, Feb. 03, 2022 (GLOBE NEWSWIRE) -- The "Clinical Trial Imaging Market Research Report by Product & Service, by Modality, by Therapeutic area, by End-User, by Region - Global Forecast to 2027 - Cumulative Impact of COVID-19" report has been added to ResearchAndMarkets.com's offering.
The Global Clinical Trial Imaging Market size was estimated at USD 908.96 million in 2020, is expected to reach USD 968.95 million in 2021, and is projected to grow at a CAGR of 6.96% to reach USD 1,456.34 million by 2027.
Market Statistics:
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2019 are considered historical years, 2020 as the base year, 2021 as the estimated year, and years from 2022 to 2027 are considered the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Clinical Trial Imaging to forecast the revenues and analyze the trends in each of the following sub-markets:
- Based on Product & Service, the market was studied across Services and Software. The Services is further studied across Operational Imaging Services, Read Analysis Services, System & Technical Support Services, and Trial Design & Consulting Services.
- Based on Modality, the market was studied across Computed Tomography, Echocardiography, Magnetic Resonance Imaging, Positron Emission Tomography, Ultrasound, and X-ray.
- Based on Therapeutic area, the market was studied across CVS, Endocrinology, Immunological Disorder, Infectious Diseases, Neurology, and Oncology.
- Based on End-User, the market was studied across Academic & Government Research Institutes, Biotechnology Companies, Contract Research Organizations, Medical Device Manufacturer, and Pharmaceutical Companies.
- Based on Region, the market was studied across the Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, and Thailand. Europe, Middle East & Africa is further studied across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Clinical Trial Imaging Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Clinical Trial Imaging Market, including anagram 4 clinical trials, BioClinica Inc., Biomedical Systems Corporation, Biospective Inc., BioTelemetry Inc., Boston Imaging Core Lab LLC., Calyx Group, Cardiovascular Imaging Technologies LLC., ICON plc., Imaging Endpoints LI, LLC, Intrinsic Imaging LLC., IXICO plc., Lyscaut Medical Imaging Company, Medical Metrics Inc., Medpace Holdings, Inc., Micron Inc., Parexel International Corporation, Perspectum Ltd., Pharmtrace klinische Entwicklung GmbH, Prism Clinical Imaging, Inc., ProScan Imaging LLC., Radiant Sage LLC., Resonance Health Ltd., and WorldCare Clinical, LLC.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Clinical Trial Imaging Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Clinical Trial Imaging Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Clinical Trial Imaging Market?
4. What is the competitive strategic window for opportunities in the Global Clinical Trial Imaging Market?
5. What are the technology trends and regulatory frameworks in the Global Clinical Trial Imaging Market?
6. What is the market share of the leading vendors in the Global Clinical Trial Imaging Market?
7. What modes and strategic moves are considered suitable for entering the Global Clinical Trial Imaging Market?
Key Topics Covered:
1. Preface
2. Research Methodology
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Significant investments made in drug development programs
5.1.1.2. Significant reduction in the drug development and approval timelines
5.1.1.3. A non-invasive method of study and usability when a biopsy is not possible
5.1.2. Restraints
5.1.2.1. Data security and privacy issues and possibility of misusing the images obtained for studies
5.1.3. Opportunities
5.1.3.1. Development of cloud-based platform simplifying the process of image sharing
5.1.3.2. Integration of artificial intelligence (AI) to minimize errors and maximize efficiency
5.1.4. Challenges
5.1.4.1. High cost associated with the imaging techniques and potential exposure to prohibitive radiation
5.2. Cumulative Impact of COVID-19
6. Clinical Trial Imaging Market, by Product & Service
6.1. Introduction
6.2. Services
6.2.1. Operational Imaging Services
6.2.2. Read Analysis Services
6.2.3. System & Technical Support Services
6.2.4. Trial Design & Consulting Services
6.3. Software
7. Clinical Trial Imaging Market, by Modality
7.1. Introduction
7.2. Computed Tomography
7.3. Echocardiography
7.4. Magnetic Resonance Imaging
7.5. Positron Emission Tomography
7.6. Ultrasound
7.7. X-ray
8. Clinical Trial Imaging Market, by Therapeutic area
8.1. Introduction
8.2. CVS
8.3. Endocrinology
8.4. Immunological Disorder
8.5. Infectious Diseases
8.6. Neurology
8.7. Oncology
9. Clinical Trial Imaging Market, by End-User
9.1. Introduction
9.2. Academic & Government Research Institutes
9.3. Biotechnology Companies
9.4. Contract Research Organizations
9.5. Medical Device Manufacturer
9.6. Pharmaceutical Companies
10. Americas Clinical Trial Imaging Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Clinical Trial Imaging Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
12. Europe, Middle East & Africa Clinical Trial Imaging Market
12.1. Introduction
12.2. France
12.3. Germany
12.4. Italy
12.5. Netherlands
12.6. Qatar
12.7. Russia
12.8. Saudi Arabia
12.9. South Africa
12.10. Spain
12.11. United Arab Emirates
12.12. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. anagram 4 clinical trials
14.2. BioClinica Inc.
14.3. Biomedical Systems Corporation
14.4. Biospective Inc.
14.5. BioTelemetry Inc.
14.6. Boston Imaging Core Lab LLC.
14.7. Calyx Group
14.8. Cardiovascular Imaging Technologies LLC.
14.9. ICON plc.
14.10. Imaging Endpoints LI, LLC
14.11. Intrinsic Imaging LLC.
14.12. IXICO plc.
14.13. Lyscaut Medical Imaging Company
14.14. Medical Metrics Inc.
14.15. Medpace Holdings, Inc.
14.16. Micron Inc.
14.17. Parexel International Corporation
14.18. Perspectum Ltd.
14.19. Pharmtrace klinische Entwicklung GmbH
14.20. Prism Clinical Imaging, Inc.
14.21. ProScan Imaging LLC.
14.22. Radiant Sage LLC.
14.23. Resonance Health Ltd.
14.24. WorldCare Clinical, LLC
15. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/8skpjt
Attachment
